These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24770508)

  • 1. Cutaneous melanoma: new advances in treatment.
    Foletto MC; Haas SE
    An Bras Dermatol; 2014; 89(2):301-10. PubMed ID: 24770508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
    Ma C; Armstrong AW
    J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
    Minutilli E; Feliciani C
    Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current advances and perspectives in the treatment of advanced melanoma.
    Livingstone E; Zimmer L; Vaubel J; Schadendorf D
    J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab and vemurafenib: two different routes for targeting melanoma.
    Burgeiro A; Mollinedo F; Oliveira PJ
    Curr Cancer Drug Targets; 2013 Oct; 13(8):879-94. PubMed ID: 23862981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New targeted therapies in melanoma.
    Kudchadkar RR; Gonzalez R; Lewis K
    Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for metastatic melanoma in 2012: dawn of a new era.
    Bhatia S; Thompson JA
    J Natl Compr Canc Netw; 2012 Mar; 10(3):403-12. PubMed ID: 22393198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current aspects of adjuvant therapy of malignant melanoma].
    Kähler KC; Egberts F; Hauschild A
    Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.